Suggested remit: To appraise the clinical and cost effectiveness of oveporexton within its marketing authorisation for treating type 1 narcolepsy.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6622
Provisional Schedule
- Committee meeting: 1:
- 09 February 2027
- Expected publication:
- 14 April 2027
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Takeda (oveporexton)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Asthma & Lung UK
- Blood Pressure UK
- Brain and Spine Foundation
- Brain Charity
- Cardiovascular Care Partnership
- Circulation Foundation
- Different Strokes
- Genetic Alliance UK
- HEART UK
- Hope2Sleep
- Narcolepsy UK
- Neurological Alliance
- Pulmonary Hypertension Association UK
- Pumping Marvellous Foundation
- Sleep Apnoea Trust
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Stroke Association
- The Sleep Charity
- Professional groups
- Association for Respiratory Technology and Physiology
- Association of British Neurologists
- Association of Respiratory Nurses
- British & Irish Hypertension Society
- British and Irish Association of Stroke Physicians
- British Association for Nursing in Cardiovascular Care
- British Cardiovascular Society
- British Geriatrics Society
- British Heart Foundation
- British Neuropathological Society
- British Sleep Society
- British Society for Heart Failure
- British Thoracic Society
- Interstitial Lung Diseases Interdisciplinary Network
- National Heart and Lung Institute
- National Neurosciences Advisory Group
- OSA Alliance
- Primary Care and Community Neurology Society
- Primary Care Cardiovascular Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Cardiological Science and Technology
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- ADVANZ Pharma (fluoxetine, venlafaxine)
- AS Kalceks (sodium oxybate)
- Aspire Pharma (venlafaxine)
- Atnahs Pharma (solriamfetol)
- Aurobindo Pharma (fluoxetine, modafinil, venlafaxine)
- Bioprojet (pitolisant)
- Brown & Burk (dexamfetamine, fluoxetine)
- Cipla (fluoxetine)
- Dexcel Pharma (venlafaxine)
- Dr. Reddy's Laboratories (fluoxetine)
- Exeltis (methylphenidate)
- Flamingo Pharma (fluoxetine)
- Flynn Pharma (methylphenidate)
- Genus Pharmaceuticals (venlafaxine)
- InfectoPharm (methylphenidate)
- Janssen-Cilag (methylphenidate)
- Krka (venlafaxine)
- Laboratorios Liconsa (methylphenidate)
- Martindale Pharma (methylphenidate, venlafaxine)
- Medice (dexamfetamine, methylphenidate)
- Morningside Healthcare (fluoxetine, venlafaxine)
- Neuraxpharm (fluoxetine, methylphenidate)
- Pinewood Healthcare (fluoxetine)
- Reig Jofre (sodium oxybate)
- Rosemont Pharmaceuticals (dexamfetamine, fluoxetine, venlafaxine)
- Sandoz (methylphenidate)
- Sovereign Medical (dexamfetamine, venlafaxine)
- Strides Pharma (fluoxetine, methylphenidate)
- Sun Pharmaceuticals (venlafaxine)
- SyriMed (fluoxetine)
- Takeda (lisdexamfetamine, methylphenidate)
- Teva Pharma (modafinil)
- UCB Pharma (sodium oxybate)
- Viatris (clomipramine, methylphenidate, venlafaxine)
- Zentiva (methylphenidate)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- Neurological Alliance of Scotland
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Wales Neurological Alliance
- Welsh Government
- Relevant research groups
- Brain Research UK
- British Association for Lung Research
- British Society for Cardiovascular Research
- Cochrane Airways Group
- Cochrane Heart, Stroke and Circulation
- Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
- European Council for Cardiovascular Research
- Genomics England
- Heart Research UK
- Institute of Neurology and Neurosurgery
- MRC Clinical Trials Unit
- National Institute for Cardiovascular Outcomes Research
- National Institute for Health & Care Research
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 July 2026 | Invitation to participate |
| 22 April 2026 - 21 May 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 22 April 2026 | In progress. Scoping commenced. |
| 18 August 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual